Offline Showroom in USA
Post Offer Free

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Hot anti-cancer medicines  > Tecentriq CAS 1380723-44-3 Atezolizumab

Tecentriq CAS 1380723-44-3 Atezolizumab 

Payment Terms: T/T,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: MOS-new6
Production Capacity: 1kg/year
Delivery Date: 7 days
Name 1: Atezolizumab
Means of Transport: Ocean,Land,Air
Packing: according to the customer's...
Name: Tecentriq
CAS: 1380723-44-3

Antibody inhibitor


CAS: 1380723-44-3

Pharmacological action and mechanism

Pd-l1 may be expressed on tumor cells and/or tumor infiltrated immune cells and may contribute to the inhibition of anti-tumor immune responses in tumor microenvironment. The binding of pd-l1 to T cells showed that pd-1 and B7.1 receptors and antigen presentation showed that the cells inhibited the activity of cytotoxic T cells, t-cell proliferation and cytokine production. Atjuzumab is a monoclonal antibody that binds to pd-l1 and blocks its interaction with pd-1 and B7.1 receptors. This release of pd-l1 / pd-1 mediated inhibition of immune responses, including activation of anti-tumor immune responses, does not induce antibody dependent cytotoxicity. In the homologous mouse tumor model, inhibition of pd-l1 activity leads to reduced tumor growth.

We can customize according to customer's requirement

if you have any question pls mail us or call us

skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Company Info


Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: